Treatment of diseases with kinase inhibitors
OwnerWilliam Biggs, Todd Carter +5inventors
InventorsWilliam Biggs, Todd Carter, Miles Fabian, David Lockhart, Patrick Zarrinkar, Daniel Treiber, Phillip Edeen
Life of this patent
Estimating the term…
Abstract
The invention is directed to the identification and use of additional targets of BIRB 796, imatinib mesylate, and BAY 43-9006. The new targets of BIRB 796, imatinib mesylate, and BAY 43-9006 can be used to screen for suitable therapeutic compounds. Also, novel therapeutic and prophylactic uses for BIRB 796, imatinib mesylate, and BAY 43-9006 are disclosed herein.
Claims31
A method of modulating an imatinib mesylate resistant tyrosine kinase activity comprising contacting a imatinib mesylate resistant tyrosine kinase polypeptide with an effective amount of BIRB-796.
A method of modulating a LCK kinase activity comprising contacting a LCK kinase polypeptide with an effective amount of imatinib mesylate.
A method of modulating a kinase activity comprising contacting a kinase polypeptide with an effective amount of BAY 43-9006 wherein said kinase polypeptide is at least one kinase selected from p38/MAPK14, imatinib mesylate resistant Abl kinase, imatinib mesylate sensitive Abl kinase, the platelet-derived growth factor receptor, and vascular endothelial growth factor receptor-2.
A method of treating an imatinib mesylate resistant tyrosine kinase-mediated disease comprising administering to an animal subject in need thereof an effective amount of BIRB-796.
A method of treating a LCK kinase-mediated disease comprising administering to an animal subject in need thereof an effective amount of imatinib mesylate.
A method of treating a kinase-mediated disease comprising administering to an animal subject in need thereof an effective amount of BAY 43-9006 wherein said kinase-mediated disease is at least one disease selected from a p38/MAPK14-mediated disease, an imatinib mesylate resistant Abl kinase-mediated disease, an imatinib mesylate sensitive Abl kinase-mediated disease, a platelet-derived growth factor receptor-mediated disease, and a vascular endothelial growth factor receptor-2-mediated disease.
A method of treating hyperplasia and/or restenosis associated with vascular grafts comprising administering to an animal subject in need thereof an effective amount of BAY 43-9006.
A method of inhibiting angiogenesis and/or growth of neovasculature comprising administering to an animal subject in need thereof an effective amount of BAY 43-9006.
A method of treating inflammation and/or inducing immunosuppression comprising contacting a LCK kinase polypeptide with a compound that binds Bcr-Abl, c-kit, and PDGFR.
A method of treating inflammation, psoriasis, and/or rheumatoid arthritis, said method comprising contacting a p38/MAPK14 polypeptide with a compound that binds Raf kinase, imatinib mesylate resistant or sensitive Abl kinase, PDGFR, and VEGFR2.
A method of treating angiogenesis comprising contacting a PDGFR and/or VEGFR2 polypeptide with a compound that binds Raf kinase, p38/MAPK14, and/or imatinib mesylate resistant or sensitive Abl kinase.
A method of treating smooth cell proliferation, intimal hyperplasia, and/or restenosis, said method comprising contacting a VEGFR2 polypeptide with a compound that binds Raf kinase, p38/MAPK14, imatinib mesylate resistant or sensitive Abl kinase, PDGFR, and VEGFR2.
A method of treating imatinib mesylate resitant chronic myelogenous leukemia comprising contacting an imatinib mesylate resistant Abl polypeptide with a compound that binds p38/MAPK14.
Dependencies are inferred from the claim text.